CARBON DIOXIDE, USP (carbon dioxide) by Carbon Biosciences is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
Carbon Dioxide, USP is an inhaled gaseous radiographic contrast agent used for X-ray imaging procedures. It functions as a contrast medium to enhance visualization of anatomical structures during diagnostic imaging. This product represents a specialized niche in diagnostic imaging with limited but specific clinical applications.
At peak lifecycle stage with moderate competitive pressure (30), suggesting stable but not high-growth commercial operations with lean team structures typical of specialized imaging agents.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Carbon Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and peak lifecycle status, this product represents a stable but non-growth career opportunity. Roles would be highly specialized in diagnostic imaging and likely involve defending market position rather than aggressive expansion.